+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Interleukin-1 alpha and interleukin-1 beta stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein



Interleukin-1 alpha and interleukin-1 beta stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein



Neuroendocrinology 57(1): 14-22



Numerous reports have demonstrated that interleukin-1 beta (IL-1 beta) is a potent secretagogue for adrenocorticotropin (ACTH) and that IL-1 alpha appears to be considerably less efficacious. To clarify apparent differences in the potency of IL-1 alpha vs. -beta on ACTH secretion from a functional perspective, the IL-1 receptor antagonist protein, IRAP, was utilized. Following administration to rats either intravenously (i.v.) or adjacent to the median eminence (intra-ME), IL-1 beta was approximately 8-fold more potent than IL-1 alpha. IRAP, delivered i.v. or intra-ME, inhibited ACTH secretion due to the administration of IL-1 alpha or -beta by the corresponding route. Similar amounts of IRAP were required to attenuate ACTH responses to approximately equieffective i.v. doses of IL-1 alpha (200 ng) or -beta (25 ng): IC50 for IRAP inhibition of IL-1 alpha vs. -beta was approximately 2.5 or 5.5 micrograms, respectively. At these IC50 doses, the ratios of IRAP/IL-1 were 12.5 and 220 for IL-1 alpha vs. -beta, respectively. These ratios are compatible with mediation by a type I-like IL-1 receptor. To compare these properties of the central IL-1 receptor to a peripheral type I IL-1 receptor in the same species, the IL-1-enhanced rat thymocyte comitogenesis assay was utilized. Thymocyte proliferation in response to equieffective doses of IL-1 alpha or -beta was similarly inhibited by IRAP:approximate IC50 for inhibition of IL-1 alpha vs. -beta was 12.5 or 25 ng/ml, respectively.

(PDF emailed within 1 workday: $29.90)

Accession: 046436519

Download citation: RISBibTeXText

PMID: 8386818


Related references

Interleukin-1 and Interleukin-1 Stimulate Adrenocorticotropin Secretion in the Rat through a Similar Hypothalamic Receptor(s): Effects of Interleukin-1 Receptor Antagonist Protein. Neuroendocrinology 57(1): 14-22, 1993

Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor (IL-2R) by a novel cytokine interleukin-1 receptor antagonist (IL-1ra). Scandinavian Journal of Immunology 36(1): 27-33, 1992

Inhibition of Interleukin-1 (Alpha and Beta), Interleukin-2 Secretion and Surface Expression of Interleukin-2 Receptor (IL-2R) by a Novel Cytokine Interleukin-1 Receptor Antagonist (IL-lra). Scandinavian Journal of Immunology 36(1): 27-34, 1992

Interleukin-8 Secretion And 15-Lipoxygenase Acuvtty In Rheumatoid Arthritis: In Vitro Anti-Inflammatory Effects By Interleukin-4 And Interleukin-10, But Not By Interleukin-1 Receptor Antagonist Protein. Rheumatology 33(6): 520-525, 1994

Interleukin-8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: in vitro anti-inflammatory effects by interleukin-4 and interleukin-10, but not by interleukin-1 receptor antagonist protein. British Journal of Rheumatology 33(6): 520-525, 1994

Polymorphisms in lymphotoxin alpha and interleukin-1 receptor antagonist genes and secretion of tumour necrosis factor alpha, soluble interleukin-2 receptor and interleukin 6 in Chinese patients with inflammatory bowel disease. Gastroenterology 114(4 PART 2): A1117, April 15, 1998

Relation of polymorphism of lymphotoxin alpha and interleukin 1 receptor antagonist genes to secretion of tumour necrosis factor alpha, soluble interleukin 2 receptor and interleukin 6 in Chinese patients with inflammatory bowel disease. Acta Academiae Medicinae Hubei 18(3): 209-213, 1997

The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1-beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers. Immunology 91(4): 548-552, 1997

Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. Journal of Clinical Immunology 17(3): 253-261, 1997

Inhibition of interleukin-1 beta mRNA expression and interleukin-1 alpha and beta secretion by a specific human recombinant interleukin-1 receptor antagonist in human peripheral blood mononuclear cells. Immunology 77(2): 245-250, 1992

A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 19(2): 382-384, 1994

Human recombinant interleukin-1 receptor antagonist blocks bone resorption induced by interleukin-1 beta but not interleukin-1 alpha. Calcified Tissue International 55(1): 12-15, 1994

Expression of interleukin-1 alpha, interleukin-1 beta, and an interleukin-1 receptor antagonist in human retinal pigment epithelial cells. Experimental Eye Research 55(2): 325-335, 1992

Human mesangial cells synthesize interleukin 1 alpha but not interleukin 1 beta, interleukin 1 receptor antagonist, or tumour necrosis factor. Nephrology, Dialysis, Transplantation 7(10): 997-1001, 1992

Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 99(3): 276-284, 2005